China grants conditional approval for Merck’s COVID treatment

Molnupiravir, developed by Merck, is approved to be used in adult patients who have mild-to-medium COVID infection and a high risk of progressing to severe cases
By Reuters on December 30, 2022

China has granted conditional approval for the import of Merck’s COVID-19 treatment Molnupiravir, China’s medical products regulator said today.

Molnupiravir, developed by Merck, is approved to be used in adult patients who have mild-to-medium COVID infection and a high risk of progressing to severe cases, according to China’s National Medical Products Administration.

Edits by EP News Bureau

 

COVID treatmentMerckNational Medical Products Administration
Related Posts

Genpact extends partnership with Ferring Pharmaceuticals to enhance operations

Lupin and NAPCON host Walkathon to raise COPD awareness

Jiangsu Hansoh ADC HS-20093 holds potential to set new standard in SCLC second-line treatment in China: GlobalData

Vyvgart Hytrulo gains first APAC approval in China, redefining CIDP care: GlobalData

Soft launch of first indigenous antibiotic to combat AMR, Nafithromycin, announced by Dr Jitendra Singh

Model N introduces Generative AI and expanded data capabilities in core solutions

360 ONE Asset acquires stake in OneSource
Comments (2)
Add Comment
  • soundos

    thanks for sharing such a nice information

  • djamila_st

    This article is an appealing wealth of informative data that is interesting and well-written. I commend your hard work on this and thank you for this information.